Outsourcing in Drug Discovery, 3rd Edition
Pages: 250
Publisher: Kalorama Information
Date Published: May 2008
Format: PDF
Price: $3500
Overview
2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations.
Kalorama Information’s Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.
Segments covered in this report include:
- Chemistry Services
- Building Blocks
- Compound Synthesis
- Libraries
- Process Research
- Other Services
- Biology Services
- Protein Expression
- Structural Analysis
- Target Validation
- Pathways Analysis
- Other Services
- Screening Services
- Assay Development
- Primary Screening
- Secondary Screening
- Lead Optimization
- Early ADMET
- Analogues Creation
- Computational Support
- Other services
In addition to market data and forecasts, the report covers issues such as:
- What factors should a client consider when deciding whether to do a project in-house or outsource it?
- Is it in the client’s best interest to seek a domestic outsourcing partner, or go with an overseas supplier?
- How does the client select the CRO that is best for him?
- What are the best practices when working with a CRO?
- How do you measure his effectiveness?
- How do you avoid problems with your CRO?
- How do you maximize benefits?
This report looks offshore at outsourcing suppliers based in three major areas: India, China, and Eastern Europe. The relative advantages each country provides are contrasted with some of their limitations. The report asses which projects are moving to which suppliers and why.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Pharmaceutical industry challenges
- Accelerating the Drug Discovery Process
- Bottlenecks in the Drug Discovery Process
- Outsourcing to Increase Efficiency
- Developing an Outsourcing Plan
- Contract Research Organization
- Strategic Versus Tactical Outsourcing Model
- Effective Communication Is Essentia
- Mitigating the Challenges of Protecting IP Rights
- Factors to Consider in Offshore Outsourcing
- Benefits of Global Outsourcing
- Cost Advantage
- Concerns about Global Outsourcing
- Outsourcing to China
- WuXi China’s Largest CRO
- First Chinese CRO Alliance
- FDA to Establish Office at US Embassay in China
- China’s Handling of IP Rights and Laws
- Outsourcing to India
- India’s Handling of IP Rights and Laws
- Outsourcing to Eastern Europe
- Current Market and Forecast Summary
CHAPTER TWO: INTRODUCTION
- Number of NME Filings in Decline While R&D Spending Rising
- Ramping Up the Pipelines
- Decision Criteria
- Factors to Consider in Offshore Outsourcing
- Benefits of Global Outsourcing
- Cost Advantage
- Access to Talent and Technologies
- Compressed Timelines
- Increased Production
- Concerns About Global Outsourcing
- Intellectual Property Protection (IP)
- Confidential Information and Trade Secrets
- Fraud and Corruption
- Meeting Regulatory Compliance Demands
- Long Distance
- Choosing the Right CRO
- Experience is Paramount
- Facility Standards
- Excellent Track Record
- Global Outsourcing
CHAPTER THREE: THE DRUG DISCOVERY PROCESS
- Target Identification
- Target Validation
- High Throughput Screening
- Lead Optimization
- Combinatorial Chemistry
- Bioinformatics/Pharmacogenomics
- ADME/Tox Screening
- High Throughput Screening
- Computational Modeling and Bioinformatics
- Outsourcing to Access Novel Technologies
- Bioinformatics
- Lab-on-a-Chip: Microfluidics in Drug Discovery
CHAPTER FOUR: OUTSOURCING DRUG DISCOVERY
- Introduction
- Role of a CRO
- Strategic Versus Tactical Outsourcing Model
- The Tactical Model
- The Strategic Model
- Effective Communication is Essential for a Successful Partnership
- Mitigating the Challenges of Protecting IP Rights
- Introduction
- Center of Gravity for the Pharmaceutical Industry Shifting from West to East
- Evolution of Contract Drug Discovery in Asia
- Introduction
- Multi-National Pharmaceutical Companies Establish Drug Discovery Facilities in China
- Chinese Contract Research Organizations
- WuXi China’s Largest CRO
- First Chinese CRO Alliance
- FDA to Establish Office at US Embassay in China
- China’s Handling of IP Rights and Laws
- IP Rights Enforcement System
- Introduction
- AstraZeneca Sets up Drug Discovery Facility in Bangalore
- Drug Discovery Services in India
- India’s Handling of IP Rights and Laws
- Patent Filing Considerations
- Limitations on Patentability
- Compulsory Licenses
- Introduction
- Russian and Ukraine CROs
CHAPTER FIVE: DRUG DISCOVERY OUTSOURCING MARKET
- Acquisitions to Gain Market Share or Entrance to the Market
- Chemistry Services Market and Forecast
- Biology Services Market
- High Throughput Screening Services Market
- Lead Optimization Services Market
- Current Market and Forecast
CHAPTER SIX: COMPETITOR PROFILES
- History and Lines of Business
- Drug Discovery Services
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- History and Lines of Business
- Drug Discovery Services
- Chemistry Services
- Biology Services
- Bridge Laboratories
- History and Lines of Business
- Drug Discovery Services
- Services in U.S.
- Services in China
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- Financial Information
- History and Lines of Business
- Drug Development Services
- History and Lines of Business
- Drug Discovery Services
- History and Lines of Business
- Drug Discovery Services
- Lead Optimization Services
- High Throughput Services
- Biologically Annotated Libraries
- Focused Diversity
- History and Lines of Business
- Drug Discovery Services
- Structural Biology Services
- High Throughput Screening & Assay Services
- Lead Optimization
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- Screening Compounds
- Screening Compounds From REAL Database®
- Lead Optimization
- Discovery Chemistry and Custom Synthesis
- Research
- History and Lines of Business
- Drug Discovery Services
- Assay Development Services
- High throughput Screening
- Medicinal Chemistry Services
- Compound Library Services
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- Bioinformatics
- Chemoinformatics
- Structural Biology
- Biology Services
- History and Lines of Business
- Drug Discovery Services
- Discovery Chemistry
- Discovery Biology
- Discovery Pharmacology
- Drug Metabolism and Pharmacokinetics (DMPK)
- History and Lines of Business
- Drug Discovery Services
- History and Lines of Business
- Drug Discovery Services
- Discovery Informatics
- Discovery Research
- Drug Development
- IT Services
- History and Lines of Business
- Drug Discovery Services
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- Custom Chemical Synthesis
- Pharmacokinetics
- Metabolism Services
- Bioanalytical Services
- Structural Biology Services
- Other Biological Services
- History and Lines of Business
- Drug Discovery Services
- Lead Optimization
- ADME and Toxicity Characteristics of New Molecules
- In vivo Optimization
- Early ADME/Tox Determination
- Financial Information
- History and Lines of Business
- Drug Discovery Services
- Financial Information
- History and Lines Business
- Drug Discovery Services
- Medicinal Chemistry
- Custom Synthesis
- High Throughput Purification & Analysis
- ADMET & Bioanalytical Services
- Bioanalytical Capabilities
- Data Management And Collaboration
- History and Lines of Business
- Drug Discovery Services
- Discovery Chemistry
- Library Generation
- Analytical Chemistry
- Medicinal Chemistry
- ADME Studies
- Natural Product Chemistry
- Computational Chemistry and Drug Design
- History and Lines of Buisness
- Drug Discovery Services
- Discovery Chemistry Services
- Exhibit 1-1: Drug Discovery Timeline: Research to Viable Product to Commercialization
- Exhibit 1-2: NMEs and New BLAs Filed, 1996-2007
- Exhibit 1-3: Global R&D Spending, 1996-2007
- Exhibit 1-4: Global Drug Discovery Outsourcing Market 2005-2013
- Exhibit 1-5: Share of Outsourced Drug Discovery Market by Segment
- (Biology Services, Chemistry Services, Lead Optimization, High
Throughput Screening) 2007
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER TWO: INTRODUCTION
CHAPTER THREE: THE DRUG DISCOVERY PROCESS
CHAPTER FOUR: OUTSOURCING DRUG DISCOVERY
CHAPTER FIVE: DRUG DISCOVERY OUTSOURCING MARKET
